A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis.
Qizhi Ma, Xia He, Benxia Zhang...
https://pubmed.ncbi.nlm.nih.gov/36402752/Actively Recruiting
Early Phase 1
Age: 18Years - 75Years
All Genders
ID04684459
Phase I Study of Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy for HER2-positive Solid Tumors
Led by Sichuan University · Updated on 2024-10-30
18
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying a new dual-targeting CAR-T cell therapy for patients with HER2-positive solid tumors, including breast, ovarian, lung, gastric, and other cancers. This early-phase trial aims to enhance the ability of CAR-T cells to fight tumors by transforming an inhibitory signal into an activation signal in the tumor environment. The study focuses on evaluating safety and side effects, as well as initial effectiveness in controlling tumor growth.
CONDITIONS
Brief Title
Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors
Research Team
Q
Qizhi Ma, Dr
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here